Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. APL-2 in PNH Subjects (PADDOCK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02588833|
Recruitment Status : Recruiting
First Posted : October 28, 2015
Last Update Posted : April 10, 2018
The objectives of the study are to assess the safety, tolerability, preliminary efficacy and PK of multiple subcutaneous (SC) doses of APL-2 in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received treatment with eculizumab in the past.
An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC doses of APL 2 when administered to PNH patients.
|Condition or disease||Intervention/treatment||Phase|
|Paroxysmal Nocturnal Hemoglobinuria||Drug: APL-2||Phase 1|
This is a Phase Ib, open-label, multiple ascending dose, pilot study in patients with PNH who have not received eculizumab (Soliris)® in the past. Two cohorts of 3 subjects are planned for evaluation.
Safety will be assessed throughout the study; serial blood and urine samples will be collected for these assessments. Blood samples will be collected for the assessment of APL 2 PK. Additional samples for assessment of PD will also be collected.
The study will consist of four parts;
- Part 1: subjects will receive APL-2 for 28 days.
- Part 2A: subjects may continue to receive APL-2 for a further 56 days if there is evidence of perceived clinical benefit following review of available safety, PK and PD data by the investigator and sponsor
- Part 2B: subjects may continue to receive daily APL-2 treatment for up to 364 days if there is ongoing evidence of clinical benefit following review of the available safety, PK and PD data.
- Part 3: Safety follow up Screening will take place within 30 days prior to the start of dosing on Day 1. If needed (see inclusion criteria), Neisseria menigitides types A, C, W, Y and B (administered as two separate vaccinations), Pneumococcal conjugate vaccine or Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23, respectively), and Haemophilus influenzae Type B (Hib) vaccinations will be administered at least 14 days prior to dosing on Day 1.
Subjects will be entered into Part 1 of the study on Day 1 at a time designated by the PI. During Part 1, the first 3 daily SC doses of APL-2 (Day 1 to 3) as well as doses on Day 8, 15 and 22 will be administered at the clinical site. From Day 4 to Day 28 daily doses of APL-2 will be administered off-site by a trained study nurse at the subject's home, workplace, or other location convenient to the subject with the exception of those days where dosing is at the clinical site. Following ongoing review of available safety, PK and PD data by the investigator and sponsor, subjects showing evidence of perceived clinical benefit may progress to Part 2A and then to Part 2B of the study and continue to receive daily doses of APL 2 until Day 84 and then until Day 364.
Cohort 2 will not be initiated until all subjects in Cohort 1 have reached the Day 29 visit and the SMC has reviewed emerging safety and efficacy data and determined that, at the initial dose, APL-2 has an acceptable safety and tolerability profile.
The planned length of participation in the study for each subject in Cohort 2 is approximately 444 days (14.5 months) from Day 30 through completion of the Day 414 Exit visit procedures).
The study is planned to take place over approximately 24 months (from screening of Cohort 1 through completion of Cohort 2).
This time period may change in the event that the study is terminated early, additional cohorts are enrolled, additional time is required to review safety between cohorts, or extended safety and PK sampling is added for a cohort.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)|
|Study Start Date :||November 2015|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||September 2019|
Experimental: Cohort 1
180 mg APL-2/day
Experimental: Cohort 2
270 mg APL-2/day
Experimental: Cohort 2 (Intra-subject)
Intra-subject escalation up to 360 mg APL-2/day
- Number of treatment emergent adverse events (TEAEs) following administration of multiple doses of SC APL-2. [ Time Frame: changefrom baseline ]
- Severity of treatment emergent adverse events (TEAEs) following administration of multiple doses of SC APL-2. [ Time Frame: change from baseline ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02588833
|Prince of Wales Hospital||Recruiting|
|Hong Kong, Hong Kong|
|Contact: Raymond Wong +852 73821966 email@example.com|
|Queen Mary Hospital||Not yet recruiting|
|Hong Kong, Hong Kong|
|Contact: Eric TSE 852 2255 3975 firstname.lastname@example.org|
|Ampang, Selangor, Malaysia, 68000|
|Contact: Jameela SATHAR 60193889996 email@example.com|
|Hamilton, Waikato, New Zealand, 3240|
|Bangkok Hospital (Wattanosoth)||Not yet recruiting|
|Bangkok, Thailand, 10310|
|Contact: Surapol ISSARAGRISIL 66819143828 firstname.lastname@example.org|
|Rajavithi Hospital||Not yet recruiting|
|Bangkok, Thailand, 10400|
|Contact: Kunapa IAM-ARUNTHAI 66873290921 email@example.com|
|Bangkok, Thailand, 10400|
|Contact: Pimjai Niparuck 66868371441 firstname.lastname@example.org|
|Bangkok, Thailand, 10700|
|Contact: Surapol Issaragrisil 66819143828 email@example.com|
|Contact: Tontanai NUMBENJAPON 66802492227 firstname.lastname@example.org|
|Study Director:||Federico Grossi, MD, PhD||Apellis Pharmaceuticals, Inc.|